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A single step ion-exchange chromatography on a sulfo-propyl (SP)- Sepharose column was performed to 
separate both the high molecular weight (HMW)- and low molecular weight (LMW)- forms of enzymatically 
active urokinase type plasminogen activator from human kidney (HT1080) cell culture media. The level of 
urokinase secreted by the cell line reached to about 145 Plough units/ml culture broth within 48 h of 
cultivation. The conditioned cell culture media was applied directly to the column without any prior 
concentration steps. Polyacrylamide gel electrophoresis of the column eluates in the presence of sodium 
dodecyl sulphate showed that the cell line secretes three forms of two-chain high molecular weight (HMW) 
urokinase of molecular weights (Mr) 64,000, 60,900 and 55,000. In addition, two low molecular weight (LMW) 
forms of Mr 22,000 and 20,000; proteolytic cleavage products of HMW, were also found. The HMW and LMW 
forms had intrinsic plasminogen dependent proteolytic activity as judged by zymographic analysis. The 
specific activity of the pooled peak fractions increased (approximately 93-fold) to values as high as 1481 Plough 
units/ mg protein. Both HMW as well as LMW forms were obtained in significantly high yields. 
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activator, Single step purification 
1.  Introduction 
Urokinase (UK; EC 3.4.21.73), a plasminogen 
activating proteolytic enzyme, was first described in 
1951 as occurring in trace quantities in mammalian 
urine [1]. The urokinase detected in urine is produced 
by kidney cells. It has been reported that the 
urokinase secreted by kidney cells is antigenically 
similar to the one isolated from urine [2]. Urokinase 
catalyzes the conversion of plasminogen to plasmin 
by cleaving the Arg-Val linkage in the Pro-Gly-Arg-
Val sequence of the former. As the resulting plasmin 
dissolves clots of fibrin in blood vessels, urokinase is 
intravenously administered for treatment of 
thromboembolic disease [3]. There are two kinds of 
this enzyme, the low molecular weight (LMW-) and 
the high molecular weight (HMW-) urokinase. The 
former being an autocatalytic fragmentation product 
of the latter [4] and both these forms are 
glycoproteins [5].  
All characterized commercial preparations of 
urokinase contain one or both of these enzymatically 
active forms. The major source of commercially 
available urokinase is human urine [6]. However, 
extremely low concentrations of urokinase (10-15 
μg/ml) in human urine create a major problem in 
isolation and purification of this enzyme [7]. Human 
kidney cells cultured in vitro, are a recognized source 
of urokinase. These cells are known to secrete 
biologically active and heavily glycosylated urokinase 
in the culture medium [2]. The yields of this enzyme 
are relatively low. In order to enhance the urokinase 
production by these cells it i s  r e q u i r e d  t o  d e s i g n  
operational strategies and perform media 
optimizations for the growth of the cells and enzyme 
production. Moreover, urokinase production per unit 
confluent area and per unit time must be increased. 
This potential for increased secretion of urokinase by 
cells is an important consideration for using cell 
culture for urokinase production. Attempts are being 
made to have an insight for separation of urokinase 
from cell culture broth. In view of this therapeutic 
importance of obtaining a plasminogen activator from 
a human source, we have been working on the 
urokinase production using human kidney cell line 
HT1080. The cell lines, however, must be fed with a 
complex growth medium. This need for nutrients 
such as sugars, amino acids and growth factors, is 
supplied from preparations of animal serum in the 
growth medium.  
The separation strategies devised till date in-
volve a series of concentration steps followed by con-
ventional chromatographic separations [8]. In one 
such reported work, Hou and Zaniewski [6] purified 
urinary urokinase by an SP cation exchanger followed 
by a zinc-chelated affinity chromatographic cartridge. 
This report demonstrated the combined use of a 
cation exchanger with zinc-chelated chromatographic 
cartridges in purifying urokinase on a relatively large 
scale with an 18-fold increase in urokinase specific 
activity and approximately 70 % yield. Multi-step 
chromatographic methods have also been reported 
for the separation of urokinase from conditioned cell 
culture media of different human cell lines [9, 10]. 
Similarities in the structures of known synthetic sub-
strates and inhibitors of urokinase have led to the for-
mulation of suitable competitive inhibitors for affinity 
chromatography ligands such as BAPA (α-benzylsul-Int. J. Biol. Sci. 2007, 3  65
fonyl-p-aminophenylalanine) [11], aminobenzamidine 
[12], homoarginine benzyl ester [13] or agmatine [14, 
15] coupled to a gel matrix. However, these adsorb-
ents do not exhibit specificity to yield highly purified 
urokinase. Immunoaffinity chromatography offers a 
powerful approach for the separation of urokinase 
from cell culture broth [16]. However, because of the 
high costs and low operational stability of the anti-
body columns, such approach suffers some limita-
tions. Most of the isolation methods for urokinase use 
multi-step approach which lead to lower yields cou-
pled with high capital and operating costs, thus mak-
ing cost-effective and high-fold purification of 
urokinase from crude sources a major challenge. Thus 
the new developments for efficient and cost effective 
separation strategies for urokinsae are highly desired.  
The present work describes a single-step 
purification process for the separation of urokinase 
from the conditioned media obtained from the hu-
man kidney (HT1080) cell cultures.  
2.  Materials and Methods 
Materials 
Urokinase from human kidney cells (activity 
0.37 Sigma units/mg protein), plasminogen (bovine 
plasma) and urokinase substrate (pyro-Glu-Gly-Arg-
p-nitroanilide-HCl) were obtained from Sigma (St 
Louis, MO, USA). Casein for zymography was 
purchased from ICN Biomedicals Inc. (Aurora, USA). 
Medium range protein molecular weight marker was 
bought from Bangalore Genei Private Ltd. (Banglore, 
India). Centriplus YM-30 and Centriplus YM-10 were 
purchased from Amicon. 
Cell culture medium, Dulbecco’s Modified 
Eagles medium (DMEM) and New Born Calf Serum 
(NBCS) were from Life Technologies (Gibco BRL). 
Sulfo Propyl (SP)-Sepharose®  Fast Flow from 
Pharmacia Fine Chemicals (Uppsala, Sweden) was a 
kind gift from Dr. Panda (NII, India). All other 
chemicals were of analytical reagent grade and used 
without further purification. 
Cell line 
Human kidney cell line HT1080 (NCCS, Pune, 
India) was cultured in DMEM containing 10 % NBCS. 
Conditioned media samples were withdrawn from 
the T-flasks at regular intervals to monitor urokinase 
production. The media withdrawn between 48 and 72 
hours of cell cultivation was pooled and used as the 
source material for urokinase purification. 
Ammonium sulphate precipitation 
Powdered ammonium sulphate was added (in 
small aliquots) to the conditioned media kept in ice to 
approximately 50 % saturation with constant stirring. 
The precipitate was collected by centrifugation at 
8,000 g for 30 min. The pellet was then resuspended 
in 500 μl of 0.05 M Tris-HCl buffer, pH 8.0. 
Resuspended pellet samples were dialyzed overnight 
against the suspension buffer (50 mM Tris-HCl, pH 
8.0) and assayed for protein concentration and 
urokinase activity. 
Centrifugal filtration 
Centrifugal filtration modules, Centriplus YM-
30 and Centriplus YM-10 were used to concentrate 
the urokinase activity in conditioned cell culture 
media. The conditioned media was filtered through 
these modules at 4,000 g for 1 hour at 4°C. 
Ion-exchange chromatography 
SP-Sepharose (3.0 ml) was washed in 0.5 M 
NaOH according to the manufacturer’s instructions. 
Thereafter, the gel was washed with distilled water 
and packed in a 1.0 x 10-cm column (Pharmacia Fine 
Chemicals) to a length of about 3.0 cm. The gel was 
then equilibrated with 50 mM sodium acetate buffer, 
pH 4.5 containing 5 mM EDTA, at a flow rate of 0.1 
ml/min. Three milliliters of the cell culture broth, 
predialysed against equilibration buffer were applied 
to the column. The column was then washed using 
five column volumes of pre-elution buffer (0.2 M 
NaCl, 50 mM sodium acetate, 5mM EDTA, pH 4.5) to 
remove unbound or loosely proteins. The bound 
urokinase was subsequently eluted with 40 ml of 
linear gradient of 0.2 M – 2.0 M NaCl in 50 mM 
sodium acetate buffer, pH 4.5 containing 5 mM EDTA 
at a flow rate of 0.1 ml/min. Fractions of 1.0 ml each 
were collected and those containing the protein peak 
were assayed for urokinase activity and desalted by 
dialysis. 
Analytical methods 
 Enzyme assay:  Amidolytic activity of urokinase 
was determined by the method of Tait et al. [17], 
using  pyro-Glu-Gly-Arg-p-nitroanilide-HCl as 
urokinase substrate. The activity units were 
expressed as Plough units/mg protein and were 
determined by using urokinase from human kidney 
cells (0.37 Sigma units/mg protein; 1 Sigma unit = 75 
000 Plough units) as standard.  One Sigma unit 
corresponds to the amount of enzyme that hydrolyzes 
1  μmol pyro-Glu-Gly-Arg-p-nitroanilide-HCl per 
minute at 37 °C and at pH 8.8.  
Protein measurements: The amount of protein was 
determined by Folin´s method according to Lowry et 
al. [18], using bovine serum albumin (BSA) as a 
standard. 
Sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE): The electrophoresis was 
performed according to the method of Laemmli [19], 
using 4-10 % gradient gel. Reduction of protein was 
accomplished with 10 % β-mercaptoethanol (v/v) in 
the sample buffer. Gels were stained with 0.1 % 
Coomasie blue in 50 % methanol and 10 % acetic acid 
for 1 hour followed by destaining in 7 % methanol 
and 7 % acetic acid till the background reduced to the 
extent of convenient visibility of the protein bands on 
the gel. The molecular weights of samples were 
determined by SDS-PAGE using medium range 
protein molecular weight marker (PMW-M). 
Zymography:  The  Zymography for urokinase 
activity was performed by modification of the 
method by Heussen and Dowdle [20]. Samples 
(mixed with sample buffer containing 10 % SDS and 
40 % glycerol (v/v) but without β-mercaptoethanol) 
were loaded on to 10 % SDS-PAGE gels containing 0.1 
% casein with 7.5 μg/ml of plasminogen at 4°C. The 
gels were then treated with 100 ml of 50 mM Tris-HCl 
(pH 7.5) containing 2.5 % Triton X-100 for 1 hour at 
room temperature with gentle shaking. The gels were 
then washed in 100 ml deionized water for 10 min, 
and incubated in 0.1 M glycine-NaOH (pH 8.3) Int. J. Biol. Sci. 2007, 3  66
overnight at 37°C with gentle shaking. Finally, these 
were stained with Coomasie brilliant blue. Urokinase 
(Sigma) was used as a positive control. 
3.  Results  
Concentration of urokinase activity in starting 
material 
Human kidney cell line HT 1080 was cultured in 
DMEM containing 10% NBCS. The cells adhered to 
the tissue culture dish and full confluence was 
obtained within 48 h of cell cultivation (Fig. 1). The 
conditioned media samples withdrawn at regular 
intervals were assayed for urokinase activity. The 
cells secreted about 145 PU/ml culture broth at 48 h 
of cell cultivation (Fig. 2). The slight decreases in 
activity observed latter are because of the secretion of 
urokinase inhibitors by the cell line.  
The specific activity of urokinase in the 
resuspended and subsequently dialyzed pellet 
obtained from 50 % ammonium sulphate saturation 
of the conditioned medium from cell culture showed 
an approximately 4-fold increase. However, the 
recovery of urokinase was only about 20 %. 
Centrifugal filtration was then tried as an 
alternative to ammonium sulphate precipitation. The 
conditioned cell culture media was concentrated by 
means of centrifugal filtration through 10 kD and 30 
kD cut off centriplus modules. Urokinase activity was 
detected in both the retentate as well as permeate. 
The centriplus was consequently treated with BSA 
prior to the filtration process. However, no 
considerable increase in recovery could be achieved. 
Thus both ammonium sulphate precipitation and 
ultrafiltration were not successful for the 
concentration of the enzyme either because of the low 
recoveries or loss of the enzymatic activity.  
The dialyzed conditioned media from the cell 
cultures was finally applied directly to the ion-
exchange column, without any prior concentration 
step, to eliminate any possible loss in enzymatic 
activity. 
Figure 1. Growth of human kidney (HT 1080) cell line in a 
T-flask in DMEM containing 10 % NBCS. 
 
Figure 2. Secretion of urokinase by human kidney (HT 
1080) cell line. The cells are grown in 25cm
2 T-flask in 
DMEM containing 10 % NBCS. 
 
Ion-exchange chromatography 
BSA is one of the main constituents of 
conditioned media and must be removed. The pI of 
BSA is 4.7, compared to a pI in the range of 7-9 for 
urokinase [6]. Based on this difference in pI, SP-
Sepharose cation exchanger was used for binding and 
elution under acidic conditions. The use of SP-
Sepharose ion-exchange column led to as high as 93-
fold purification of urokinase (Table 1). 
Table 1. Separation of urokinase from conditioned media of human kidney (HT1080) cell culture 
Fraction Vol. 
(ml) 
Total protein 
(mg) 
Urokinase 
activity 
(PU/ml) 
Total urokinase 
(PU) 
Specific activity 
(PU/mg) 
Fold 
purification 
 
Yield 
(%) 
Conditioned cell culture 
media load 
 
3.0  26.25  140  420   16   1  100 
Breakthrough + wash 
 
30.0 
 
24.06 
 
4.92 
 
147.67 
 
 2.16 
 
 0.13 
 
 35 
 
Eluate fractions               
P1
∗  4.0   1.97   26  103.66    52.62    3.3    25 
P2
∗∗  3.0   0.21  104  311   1481  92.56   74 
∗ Peak 1 pooled fractions 
∗∗ Peak 2 pooled fractions 
 
Urokinase activity of 420 Plough units (PU) 
contained in 3.0 ml conditioned media from cell 
culture was applied to SP-Sepharose matrix packed in 
a glass column. Subsequently, the column was 
washed with pre-elution buffer to remove 
nonspecifically bound material. Most of the protein 
passed through the column unabsorbed. 
Approximately 35 % of the original urokinase activity 
appeared in the flow through and washing. 
Urokinase bound to the column was then eluted by 
the application of linear sodium chloride gradient (0.2 
– 2. 0 M NaCl). Two protein peaks were observed in 
the resulting elution profile. When the fractions 
constituting the protein peaks were analyzed for 
urokinase activity, major enzyme activity was 
observed in peak (P2). (Fig. 3, Table 1). The fractions 
constituting each of the peaks were pooled 
independently. In the first protein peak (P1) pool 
comprising fractions 6-9, about 1.97 mg of the applied Int. J. Biol. Sci. 2007, 3  67
protein constituting 103.66 PU of urokinase activity 
was recovered. This constituted 25.0 % of the enzyme 
activity loaded and resulted in a 3.3-fold increase in 
s p e c i f i c  e n z y m e  a c t i v i t y .  I n  t h e  s e c o n d  p o o l  ( P 2 )  
comprising fractions 13-15, 0.064 mg protein 
constituting about 311 PU was recovered. This 
constituted 74.0 % of the total activity loaded and 
resulted in about 93-fold increase in urokinase 
specific activity in a single step. The productivity and 
purification of the enzyme thus seems to be suitable 
for commercial production. However, it may be 
useful to consider the production of the enzyme on 
the large scale and further separation of LMW and 
HMW urokinase may be desirable. 
Figure 3. Elution profile of urokinase type-
plasminogen activator from sulfo-propyl 
Sepharose. Dialyzed conditioned culture 
media from HT1080 cells was applied to a 
column of SP-Sepharose equilibrated in 0.05 
M acetate buffer, 5mM EDTA (pH 4.5). 
After collecting the flow-through of the 
column, the column was washed with pre-
elution buffer. The bound enzyme was 
eluted by applying 40 ml of linear gradient 
of 0.2 M – 2.0 M NaCl in 50 mM sodium 
acetate buffer, pH 4.5 containing 5 mM 
EDTA at a flow rate of 0.1 ml/min. 
Diagonal line between 20 ml to 60 ml in the 
graph is the start and end of the elution gradient. Fractions 
of 1 ml were collected and assayed for protein 
concentration and enzyme activity). P1 and P2 refer to 
eluted protein peaks 1 and 2, respectively. For more details 
see materials and methods. 
 
Sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) 
The pooled fractions P1 and P2 constituting the 
chromatographic peaks 1 and 2 respectively, were 
analyzed by SDS-PAGE under reducing (Fig. 4) and 
non-reducing conditions (picture not shown). The 
pooled fractions P1 (Fig. 4, lane 3) showed presence of 
multiple bands on SDS-PAGE. The P2 pool showed 
fewer bands (Fig. 4, lane 4), as also reflected in the 
higher specific activity of urokinase so obtained by 
amidolytic assay. This lane showed a significant 
reduction in the intensity of serum albumin band that 
was distinctly visible in the band pattern obtained 
with the starting material on the gel (Fig. 4, lane 5). 
Here, the triplet bands of Mr 64,400, 60,900 and 55,000 
were not distinct and appeared faint. The two bands 
of Mr 22,000 and 20,000 seen in lane 3 were not 
observed for P2 pool. Under non-reducing conditions, 
both P1 and P 2 pooled fractions showed the presence 
of an extra band of Mr 97,000.  
The urokinase (Sigma, U5004) shown in lane 2 
(Fig. 4) was used as the reference sample for 
comparison with ion-exchange column eluates. Since 
Sigma specifications indicate 90-95 % of the total 
protein in the vial to be human albumin, therefore the 
major band (Mr 66,000) corresponded to albumin, 
while the minor band (Mr 55,000) was that of HMW 
urokinase. The LMW urokinase bands could not be 
visualized.  
Zymography 
To test the plasminogen activating potential of 
the urokinase eluted in the two peak pools, 
zymographic analysis of both the peak materials was 
performed (Fig. 5) using reference urokinase as the 
p o s i t i v e  c o n t r o l .  T h e  P 1  p o o l  f a i l e d  t o  y i e l d  a n y  
detectable zones of lysis on the zymogram (Fig. 5, 
lane 2). This may be attributed to the extremely low 
specific activity of urokinase P1 eluate. However, the 
P2 pooled fractions (Fig. 5, lane 1) produced discrete 
triplet bands of lysis in the Mr range of 64,000-55,000, 
which corresponded accurately to the triplet bands 
observed in the SDS-PAGE pattern. Two clear zones 
of Mr 22,000 and 20,000 were observed confirming the 
presence of plasminogen activating potential in the 
polypeptides eluted in P2 pool. Thus, the activity of 
urokinase was found to be well preserved in 1.0 % 
SDS. Clear bands of lysis failed to appear on a gel 
containing casein but no plasminogen thus ruling out 
the presence of any directly caseinolytic protein in the 
column eluates. Although the Mr 22,000 and 20,000 
bands were not observed on SDS-PAGE for either 
reference urokinase or the P2 pool, clear zones 
corresponding to LMW urokinase, appeared for both 
in the zymogram. This indicated a lower 
concentration of LMW as compared to HMW in the 
preparations but higher plasminogen activating 
capability. Thus, the clear zones produced by peak 
(P2) pool yielded a pattern almost identical to that 
obtained with the reference urokinase (Fig. 5, lane 3). 
Figure 4. SDS-PAGE of pooled peak fractions eluted from 
the sulfo-propyl Sepharose column. The electrophoresis 
was carried out at 20 mA. The protein samples (15 μg 
protein in each) were applied in each lane. Lanes: (1) 
molecular weight protein marker (M); (2) urokinase 
(Sigma); (3) protein peak 1 pool (P1); (4) protein peak 2 
pool (P2); and (5) conditioned media from HT1080 cell 
culture. 
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4.  Discussion 
Despite the immense clinical application of 
urokinase, no satisfactory cost efficient methods have 
yet been described for its purification from cell 
cultures. Conditioned cell culture medium contains 
relatively higher concentrations of urokinase (65 
μg/liter) [9], as compared to urine (10-15 μg/liter). 
Hence, it offers a more enriched source for urokinase 
separation. 
Figure 5. Zymogram of pooled peak fractions eluted from 
the sulfo-propyl Sepharose column. Protein (20 μg) was 
loaded in each well and electrophoresis carried out at 20 
mA at 4 °C. Lanes: (1) protein peak 2 pool (P2); (2) protein 
peak 1 pool (P1); and (3) urokinase (Sigma). Clear zones of 
lysis indicate bands of urokinase. 
 
 
I n  t h i s  s t u d y ,  c o n v e n t i o n a l  m e t h o d s  w e r e  
initially tried for concentration and partial 
purification of the enzyme, like ammonium sulphate 
precipitation or centrifugal filtration, however, these 
methods were not successful for the purpose. We 
have subsequently been able to achieve highly 
purified urokinase (1481 PU/mg protein) directly 
from the conditioned media of HT1080 cell cultures in 
a single ion-exchange chromatography step. The total 
enzyme activity mass balance obtained were 
surprisingly high (>100 %, together in breakthrough 
and eluate). This could be due to the presence of some 
enzyme-inhibitor complexes in the conditioned cell 
culture media being used as the starting material. 
Subsequently, a variation in pH or exposure to some 
nucleophilic agent during purification process might 
have led to the partial dissociation of inhibitor from 
urokinase. Consequently the percentage of free and 
active urokinase in the eluate increased. This accounts 
for nearly 100 % recovery from the ion-exchange 
column. Wun et al. [21] have also reported that HT-
1080 cell cultures allow enhanced secretion of 
plasminogen activator inhibitor-1 (PAI-1), which 
forms enzymatically inactive urokinase-PAI-1 
complexes with the urokinase. It has also been 
reported previously that a urokinase-related protein 
with M.W. 95000, representing a complex of two-
chain urokinase with an inhibitor accounts for about 
70 % of the total urokinase-related antigen in urine [9]. 
Nucleophilic agents dissociate the complex into active 
two-chain (tc) urokinase and a protein with M.W. 
54,000. This highly purified UK was obtained with a 
yield of 5 μg/l of urine. It was concluded that UK-
related proteins in human urine consist of about 25% 
of single chain (sc)-urokinase (10-20 μg/l) and of 
about 75% tc-urokinase (40-50 μg/l), the bulk of 
which is complexed to an inhibitor.  
SDS-PAGE analysis of the eluates from ion-
exchange column revealed urokinase bands in both 
the high (55-64 kD) as well as low (22-20 kD) 
molecular weight ranges (as confirmed by 
zymography). The Mr 64,000, 60,900 and 55,000 bands 
are apparently glycosylation variants of HMW 
urokinase as cultured cells are known to secrete 
differently glycosylated urokinase in the media [22]. 
The presence of these bands is in agreement with the 
findings of previous researchers wherein different 
HMW forms of urokinase (58.5±5.5 kD) have been 
reported. These forms of urokinase, upon reduction, 
produced two bands of Mr 22.0±3.5 and 20.0±3.5 as 
reported earlier [23 - 25]. This explains the presence of 
the 22,000 and 20,000 LMW bands, which are 
probably cleavage products of the HMW forms of 
urokinase. This is probably also the reason that 
urokinase activity was detected in the permeate in 
centrifugal filtration using 10 kD or 30 kD cut-off 
filters whereas the cleavage products of HMW forms 
of urokinase can be permeable. 
The HMW forms of urokinase are initially 
secreted in the media as single-chain forms. 
Autocatalytic activity of urokinase and other 
proteolytic activities present in the serum result in 
cleavage of the single chain HMW urokinase. This 
leads to the formation of two-chain HMW form in 
which two polypeptide chains are held together by 
disulphide bridges and also the LMW form [26]. 
However, addition of aprotinin, a proteolytic 
inhibitor, in the serum-supplemented media, did not 
lead to any change in urokinase composition of the 
conditioned media. Both LMW as well as HMW 
urokinase activities could still be detected in the 
media (data not shown). This observation suggested 
the presence of aprotinin-resistant proteolytic 
activities in the media. Andreasen et al. [27] have 
previously reported similar findings. 
The presence of a Mr 97,000 band in the native 
PAGE (absent in SDS-PAGE) is in agreement with the 
minor 95,000 form of urokinase reported by Booyse et 
al. [10]. Disappearance of this band from SDS-PAGE 
suggests it to be an enzyme-inhibitor complex, which 
could be dissociated into Mr 55,000 urokinase and a 
46,000-inhibitor protein on treatment with 
nucleophilic agents. Wun et al. [21], also showed that 
SDS treatment caused partial inactivation of fully or 
moderately active PAI-1 [7, 10].  
Prior to the ion-exchange chromatography step, 
attempts were made to concentrate urokinase activity 
in the conditioned media. For this purpose, classical 
techniques of ammonium sulfate precipitation, 
ethanol precipitation and centrifugal filtration were 
tried. However, neither of the precipitation 
techniques could successfully precipitate urokinase 
from the conditioned media into a single pellet. 
Centrifugal filtration also failed to yield any 
appreciable results. Appearance of activity in 
retentate as well as permeate was due to the presence 
of active forms of urokinase over a wide Mr range 
that was later confirmed through SDS-PAGE and 
zymography. The activities in the permeate and Int. J. Biol. Sci. 2007, 3  69
retentate, on being pooled together could not account 
for the total activity initially loaded on to the 
centriplus. This implied that urokinase in the medium 
(approximately 25 %) was somehow binding to the 
polysulfone membranes. Similar losses were also 
reported by others [28]. The binding of urokinase to 
polysulfone membrane might be attributed to the 
glycoprotein nature of urokinase thus leading to 
increased hydrophobic interaction between protein 
and the membrane. Even using BSA pretreated 
filtration modules or increasing the ionic strength of 
the starting material could not eliminate these losses. 
A detailed study of the glycosylation patterns of the 
purified urokinase can lead to a better understanding 
of the losses incurred during centrifugal filtration. 
It can be concluded that HT1080 cells secrete 
three forms of HMW urokinase (Mr 64,000, 60,900 and 
55,000) that are expected to be glycosylated to 
different degrees. Some proteolytic activity in the 
media, in addition to the autocatalytic activity of 
HMW urokinase, leads to fragmentation of the HMW 
form. This results in the generation of a LMW form in 
the range of Mr 22000 to 20, 000. All the forms so 
observed have been found to be enzymatically active.  
Also, as can be seen in the SDS-PAGE and 
zymography results here, the LMW and HMW forms 
of urokinase have eluted together into the same 
fraction. It has been suggested previously that it 
might be impossible to separate completely the HMW 
urokinase from the LMW form [29]. The LMW and 
HMW forms of urokinase are known to have different 
efficiencies as regards their plasminogen activating 
roles. Experiments are being conducted to achieve the 
separation of these different forms of urokinase, thus 
ensuring more homogeneous preparations of purified 
urokinase. This will be communicated shortly. 
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